Table 1.
HPV vaccination & cervical cancer screening scenarios (additional details are provided in Section 1 of technical appendix).
| Scenarios | Description |
|---|---|
| A) Main HPV vaccination & cervical cancer screening scenarios for all women | |
| Girls' vaccination (Sc1): | Routine vaccination of 9–14-year-old girls, with a 90% vaccine coverage |
| Girls' vaccination & 1 lifetime cervical screen (Sc2): | Sc1 + 1 lifetime cervical screen for women at age 35 years, with a high screening ramp-up (45% in 2023, 70% in 2030, and 90% in 2045) |
| Girls' vaccination & 2 lifetime cervical screens (Sc3)a: | Sc1 + 2 lifetime cervical screens for all women at age 35 and 45 years, with a high screening ramp-up |
| B) Main enhanced HPV vaccination & cervical screening scenarios for WLHIV | |
| Vaccination of young WLHIV (Sc4): | Sc1 + multi-age cohort vaccination of WLHIV aged 15–24 years, with 90% vaccine coverage |
| Frequent cervical screening of WLHIV (Sc5): | Sc3 + three-yearly screening of WLHIV aged 25–49 years old, with a high cervical screening ramp-up |
| Vaccination and frequent cervical screening of WLHIV (Sc6): | Sc3 +multi-age cohort vaccination of WLHIV aged 15–24 years, with 90% vaccine coverage + three-yearly screening of WLHIV aged 25–49 years old, with a high cervical screening ramp-up |
a
WHO recommended triple-intervention global cervical cancer elimination strategy.